Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“Another preclinical study showing that resistance to TOPO1i ADCs is mainly driven by payload-specific mechanisms. They tested tras-MMAF and saci-MMAF: not a practical solution for obvious reasons, but it reinforces the need for payload diversification!”
Title: Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer
Authors: Dileep Reddy Rampa, Minji Seo, Nanae Ogata, Zhaoxuan Yang, Nithya Sridhar, Fujii Takeo, Chalothorn Wannaphut, Jennifer A. Maynard, Kyoji Tsuchikama, George W. Sledge, Naoto T. Ueno, Jangsoon Lee
More posts featuring Raffaele Colombo on OncoDaily.